Cordycepin inhibits pancreatic cancer cell growth in vitro and in vivo via targeting FGFR2 and blocking ERK signaling

• Published in: Chinese journal of natural medicines Vol. 18; no. 5; pp. 345 - 355
• Main Authors: LI, Xue-Ying, TAO, Homng, JIN, Can, DU, Zhen-Yun, LIAO, Wen-Feng, TANG, Qing-Jiu, DING, Kan
• Format: Journal Article
• Language: English
• Published: China Elsevier B.V 01.05.2020
• Subjects: Animals; antineoplastic activity; Apoptosis; Apoptosis - drug effects; caspase-3; caspase-9; cell cycle checkpoints; Cell Cycle Checkpoints - drug effects; cell growth; Cell Line, Tumor; Cell Proliferation - drug effects; Cordycepin; Cordyceps - chemistry; Cordyceps militaris; cyclin-dependent kinase; cyclins; Deoxyadenosines - administration & dosage; DNA damage; drug development; Drugs, Chinese Herbal - administration & dosage; Female; FGFR2; fibroblast growth factor receptor 2; Humans; MAP Kinase Signaling System - drug effects; Mice; Mice, Inbred BALB C; neoplasm cells; Pancreatic cancer; pancreatic neoplasms; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - genetics; Pancreatic Neoplasms - metabolism; Pancreatic Neoplasms - physiopathology; phosphorylation; Ras/Erk; Receptor, Fibroblast Growth Factor, Type 2 - genetics; Receptor, Fibroblast Growth Factor, Type 2 - metabolism; Ras/Erk; Pancreatic cancer; Cordycepin; FGFR2; Apoptosis

Cordycepin (3′-deoxyadenosine) from Cordyceps militaris has been reported to have anti-tumor effects. However, the molecular target and mechanism underlying cordycepin impeding pancreatic cancer cell growth in vitro and in vivo remain vague. In this study, we reported functional target molecule of c...